Oxalic Acid

Oxalic Acid

SCHEMBL4763602

CCN1CCN(c2nc(C(O)c3ccccc3OC)cc3ccccc23)CC1.O=C(O)C(=O)O

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4769437 0.95 MEN1 (0.44) ALDH1A1USP2LMNATP53POLB
Oxalic Acid SCHEMBL4773633 0.86 ALDH1A1 (0.46) ALDH1A1USP2LMNATP53POLB
SCHEMBL4763607 0.85 ALDH1A1 (0.42) ALDH1A1USP2LMNATP53POLB
Oxalic Acid SCHEMBL4765120 0.82 CHRM5 (0.46) ALDH1A1USP2LMNATP53POLB
SCHEMBL14102717 0.81 SMN1; SMN2 (0.46) ALDH1A1LMNAPOLBMEN1KMT2A
SCHEMBL4772543 0.80 MEN1 (0.46) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
Oxalic Acid SCHEMBL6292021 0.80 ALDH1A1 (0.46) ALDH1A1LMNAMEN1KMT2ASMN1; SMN2
Oxalic Acid SCHEMBL4765656 0.80 ALDH1A1 (0.48) ALDH1A1USP2LMNATP53POLB
Oxalic Acid SCHEMBL6288628 0.78 KDM4E (0.43) ALDH1A1USP2LMNATP53POLB
Oxalic Acid SCHEMBL6288629 0.78 KDM4E (0.43) ALDH1A1USP2LMNATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ALDH1A1 2989/4885USP2 3459/4885LMNA 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.